ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 Shares

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 2,976 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $10.01, for a total transaction of $29,789.76. Following the transaction, the chief financial officer now directly owns 102,117 shares in the company, valued at $1,022,191.17. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Dominic Piscitelli also recently made the following trade(s):

• On Thursday, June 12th, Dominic Piscitelli sold 300 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Friday, June 6th, Dominic Piscitelli sold 2,600 shares of ORIC Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total transaction of $26,026.00.

ORIC Pharmaceuticals Price Performance

NASDAQ:ORIC traded down $0.04 during trading hours on Friday, hitting $9.63. 714,124 shares of the company were exchanged, compared to its average volume of 775,451. The stock has a market capitalization of $820.71 million, a price-to-earnings ratio of -5.29 and a beta of 1.49. ORIC Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.67. The company's 50 day moving average price is $6.15 and its 200-day moving average price is $7.69.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.09. On average, equities analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Institutional Trading of ORIC Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC grew its position in ORIC Pharmaceuticals by 56.0% during the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock worth $174,000 after purchasing an additional 11,198 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in ORIC Pharmaceuticals by 1,331.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock valued at $2,841,000 after acquiring an additional 473,600 shares during the period. Goldman Sachs Group Inc. lifted its stake in ORIC Pharmaceuticals by 9.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock valued at $1,645,000 after acquiring an additional 24,778 shares during the period. Parkman Healthcare Partners LLC acquired a new stake in ORIC Pharmaceuticals during the 1st quarter valued at approximately $1,133,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in ORIC Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock valued at $226,000 after acquiring an additional 3,131 shares during the period. Hedge funds and other institutional investors own 95.05% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on ORIC shares. Wedbush reissued an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Thursday, May 29th. Guggenheim reaffirmed a "buy" rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research report on Monday, May 5th. JPMorgan Chase & Co. lifted their price objective on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $19.17.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.